Ramesh Narayanan from 487 Herring Ln, Cordova, TN 38018, age 55, Phone: (901)3092002

Resumes

Director, Drug Discovery

view source

Position:

Director, Drug Discovery at GTx, Inc.

Location:

Greater Memphis Area

Industry:

Pharmaceuticals

Work:

GTx, Inc. since Jan 2011
Director, Drug Discovery
The University of Tennessee - Greater Memphis Area Jun 2006 - Jan 2013
Adjunct Associate Professor
GTx, Inc. Jan 2005 - Dec 2010
Senior Scientist, Drug Discovery
Baylor College of Medicine - Houston, Texas Area Jun 1998 - Dec 2004
Post Doctoral Fellow
Rush presbyterian St.Lukes Medical Center Jun 1997 - May 1998
Post Doctoral Fellow

Education:

The University of Memphis 2007 - 2009
M.B.A., Global Business University of Madras 1994 - 1998
Ph.D., Biochemistry & Molecular Biology

Skills:

Drug Discovery
Biotechnology
Molecular Biology
Oncology
Pharmacology
Biochemistry
Lifesciences
Pharmacodynamics
Pharmaceutical Industry

Vertica Technical Consultant At Hp Vertica

view source

Position:

Vertica Technical Consultant at HP Vertica

Location:

Coppell, Texas

Industry:

Information Technology and Services

Work:

HP Vertica - Greater Boston Area since Jul 2013
Vertica Technical Consultant
FosterSoft, Inc. - Greater Salt Lake City Area Jun 2013 - Jun 2013
Senior Sybase Consultant
AIG - Dallas/Fort Worth Area Aug 2012 - May 2013
Senior Sybase Consultant
Handmark Feb 2009 - Jul 2012
Senior Database Analyst / Architect
Travelocity Mar 2008 - Jan 2009
Manager Systems Engineering

Education:

University of Maryland University College 2001 - 2004
Masters, Computer Systems Management

Ramesh Narayanan

view source

Location:

United States

Ramesh Narayanan

view source

Location:

United States

Ramesh Narayanan

view source

Location:

United States

Ramesh Narayanan

view source

Location:

Sammamish, Washington

Industry:

Computer Software

Ramesh Narayanan

view source

Location:

United States

Ramesh Narayanan Cordova, TN

view source

Work:

GTx Inc

Jan 2011 to 2000
Director, Drug Discovery University of Tennessee

Sep 2006 to 2000
Adjunct Associate Professor GTx Inc
Memphis, TN
Jan 2005 to Dec 2010
Senior Scientist and group leader, Drug Discovery Baylor College of Medicine
Houston, TX
Jun 1998 to Dec 2004
Post Doctoral Fellow, Department of Molecular and Cellular Biology

Education:

The University of Memphis, Fogelman College of Business and Economics
2009
MBA in Entrepreneurship The University of Madras
2000
Ph.D. in Biochemistry Annamalai University
1994
M.S. in Biochemistry The University of Madras
1991
B.S. in Chemistry

Us Patents

Nuclear Receptor Binding Agents
view source
US Patent:

8158828, Apr 17, 2012
Filed:

Apr 16, 2007
Appl. No.:

11/785251
Inventors:

James T. Dalton - Upper Arlington OH, US
Christina Barrett - Oakland TN, US
Yali He - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Memphis TN, US
Assignee:

GTx, Inc. - Memphis TN
International Classification:

C07C 233/65
A61K 31/165
US Classification:

564179, 564170, 564176, 564177, 514617
Abstract:

The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.

Nuclear Receptor Binding Agents
view source
US Patent:

8637706, Jan 28, 2014
Filed:

Jan 31, 2012
Appl. No.:

13/362242
Inventors:

James T. Dalton - Lakeland TN, US
Christina Barrett - Oakland TN, US
Duane D. Miller - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Yali He - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Collierville TN, US
Assignee:

Gtx, Inc. - Memphis TN
International Classification:

C07C 233/65
A61K 31/165
US Classification:

564179, 564171, 514617, 514619
Abstract:

The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.

Nuclear Receptor Binding Agents
view source
US Patent:

20090062341, Mar 5, 2009
Filed:

Nov 28, 2006
Appl. No.:

11/604884
Inventors:

James T. Dalton - Upper Arlington OH, US
Christina Barrett - Oakland TN, US
Yali He - Germantown TN, US
Seoung-Soo Hong - Collierville TN, US
Duane D. Miller - Germantown TN, US
Michael L. Mohler - Memphis TN, US
Ramesh Narayanan - Cordova TN, US
Zhongzhi Wu - Memphis TN, US
International Classification:

A61K 31/4545
C07C 233/64
A61K 31/166
A61K 31/445
C07D 401/02
C07K 14/72
C07D 211/60
C07D 213/81
A61K 31/44
US Classification:

514318, 564176, 514622, 514317, 546215, 546323, 514354, 546194, 530409
Abstract:

The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.

Nuclear Receptor Binding Agents
view source
US Patent:

20100267767, Oct 21, 2010
Filed:

May 4, 2010
Appl. No.:

12/773515
Inventors:

Ramesh NARAYANAN - Cordova TN, US
Muralimohan Yepuru - Bartlett TN, US
James T. Dalton - Lakeland TN, US
International Classification:

A61K 31/472
A61P 3/04
A61P 3/00
A61P 29/00
A61P 9/00
A61P 9/12
C07D 217/22
US Classification:

514309, 546141
Abstract:

The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

Aldo-Keto Reductase Subfamily 1C3 (Akr1C3) Inhibitors
view source
US Patent:

20130116277, May 9, 2013
Filed:

Sep 7, 2012
Appl. No.:

13/607633
Inventors:

James T. DALTON - Lakeland TN, US
Duane D. Miller - Germantown TN, US
Ramesh Narayanan - Cordova TN, US
Muralimohan Yepuru - Bartlett TN, US
Christopher C. Coss - Bartlett TN, US
Michael L. Mohler - Memphis TN, US
Zhongzhi Wu - Collierville TN, US
International Classification:

C07D 217/24
US Classification:

514309, 546141
Abstract:

The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma.

Method Of Treating Androgen Receptor (Ar) -Positive Breast Cancers With Selective Androgen Receptor Modulator (Sarms)
view source
US Patent:

20140018433, Jan 16, 2014
Filed:

Mar 7, 2013
Appl. No.:

13/789005
Inventors:

Mitchell S. Steiner - Germantown TN, US
Ramesh Narayanan - Cordova TN, US
Sunjoo Ahn - Memphis TN, US
International Classification:

C07C 271/02
A61K 45/06
A61K 31/325
US Classification:

514620
Abstract:

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.

Method Of Treating Estrogen Receptor (Er) -Positive Breast Cancers With Selective Androgen Receptor Modulator (Sarms)
view source
US Patent:

20140080905, Mar 20, 2014
Filed:

Jul 29, 2013
Appl. No.:

13/953492
Inventors:

Mitchell S. Steiner - Germantown TN, US
Ramesh Narayanan - Cordova TN, US
Sunjoo Ahn - Daejeon, KR
Assignee:

GTx, Inc. - Memphis TN
International Classification:

C07C 255/60
C07C 237/20
US Classification:

514522, 514616
Abstract:

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.

Non-Invasive Method Of Evaluating Breast Cancers For Selective Androgen Receptor Modulator (Sarm) Therapy
view source
US Patent:

20210128513, May 6, 2021
Filed:

Oct 9, 2020
Appl. No.:

17/066487
Inventors:

- KNOXVILLE TN, US
Ramesh NARAYANAN - Cordova TN, US
Sunjoo AHN - Daejeon, KR
James T. DALTON - Ann Arbor MI, US
Assignee:

UN IVERSITY OF TENNESSEE RESEARCH FOUNDATION - KNOXVILLE TN
International Classification:

A61K 31/277
A61K 31/167
A61P 35/00
A61K 31/404
A61K 31/4704
Abstract:

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio)), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and/or treating breast cancer in a subject, by first determining the F-16β-fluoro-5α-dihydrotestosterone (F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.